We have located links that may give you full text access.
The Association of Lipoprotein(a) and Coronary Artery Calcium in Asymptomatic Patients: A Systematic Review and Meta-analysis.
European Journal of Preventive Cardiology 2024 Februrary 2
AIMS: Lipoprotein(a) [Lp(a)] is an atherogenic lipid particle associated with increased risk for coronary heart disease (CHD) events. Coronary artery calcium (CAC) score is a tool to diagnose subclinical atherosclerosis and guide clinical decision-making for primary prevention of CHD. Studies show conflicting results concerning the relationship between Lp(a) and CAC in asymptomatic populations. We conducted a meta-analysis to evaluate the association of Lp(a) and CAC in asymptomatic patients.
METHODS: We systematically searched PubMed, Embase, and Cochrane until April 2023 for studies evaluating the association between Lp(a) and CAC in asymptomatic patients. We evaluated CAC>0 Agatston units, and CAC>100. Lp(a) was analysed as a continuous or dichotomous variable. We assessed the association between Lp(a) and CAC with pooled odds ratios (OR) adopting a random-effects model.
RESULTS: A total of 23,105 patients from 18 studies were included in the meta-analysis with a mean age of 55.9 years, 46.4% female. Elevated Lp(a) increased the odds of CAC>0 (OR 1.31; 95% CI 1.05 to 1.64; p=0.02), CAC ≥100 (OR 1.29; 95% CI 1.01 to 1.65; p=0.04; ), and CAC progression (OR 1.43; 95% CI 1.20 to 1.70; p<0.01; ). For each increment of 1 mg/dL in Lp(a) there was a 1% in the odds of CAC>0 (OR 1.01; 95% CI 1.01 to 1.01; p<0.01).
CONCLUSIONS: Our findings of this meta-analysis suggest that Lp(a) is positively associated with a higher likelihood of CAC. Higher Lp(a) levels increased the odds of CAC >0. These data support the concept that Lp(a) is atherogenic, although with high heterogeneity and a low level of certainty.
PROTOCOL REGISTRATION: CRD42023422034.
METHODS: We systematically searched PubMed, Embase, and Cochrane until April 2023 for studies evaluating the association between Lp(a) and CAC in asymptomatic patients. We evaluated CAC>0 Agatston units, and CAC>100. Lp(a) was analysed as a continuous or dichotomous variable. We assessed the association between Lp(a) and CAC with pooled odds ratios (OR) adopting a random-effects model.
RESULTS: A total of 23,105 patients from 18 studies were included in the meta-analysis with a mean age of 55.9 years, 46.4% female. Elevated Lp(a) increased the odds of CAC>0 (OR 1.31; 95% CI 1.05 to 1.64; p=0.02), CAC ≥100 (OR 1.29; 95% CI 1.01 to 1.65; p=0.04; ), and CAC progression (OR 1.43; 95% CI 1.20 to 1.70; p<0.01; ). For each increment of 1 mg/dL in Lp(a) there was a 1% in the odds of CAC>0 (OR 1.01; 95% CI 1.01 to 1.01; p<0.01).
CONCLUSIONS: Our findings of this meta-analysis suggest that Lp(a) is positively associated with a higher likelihood of CAC. Higher Lp(a) levels increased the odds of CAC >0. These data support the concept that Lp(a) is atherogenic, although with high heterogeneity and a low level of certainty.
PROTOCOL REGISTRATION: CRD42023422034.
Full text links
Related Resources
Trending Papers
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Review article: Recent advances in ascites and acute kidney injury management in cirrhosis.Alimentary Pharmacology & Therapeutics 2024 March 26
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app